Literature DB >> 12874452

Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP.

Praveen N Chander1, Ricardo Rocha, Jeffrey Ranaudo, Gagan Singh, Andrea Zuckerman, Charles T Stier.   

Abstract

Angiotensin-converting enzyme inhibitors and aldosterone receptor antagonists ameliorate malignant nephrosclerotic lesions of thrombotic microangiopathy in salt-loaded, stroke-prone, spontaneously hypertensive rats (SHRSP) without controlling hypertension. This suggests that angiotensin II (Ang II) and/or aldosterone (ALDO) plays a critical role in renal injury in this model. For evaluating their relative roles in the pathogenesis of thrombotic microangiopathy, SHRSP were adrenalectomized and infused with vehicle, Ang II, or ALDO or were sham-operated for adrenalectomy (SHAM). Saline-drinking rats were assigned to one of four groups: SHAM, adrenalectomy, adrenalectomy + Ang II (25 ng/min, subcutaneously), or adrenalectomy + ALDO (40 micro g/kg per d, subcutaneously). All SHRSP received dexamethasone (12 micro g/kg per d, subcutaneously). Adrenalectomy did not show changes in body weight, plasma creatinine, sodium and potassium, and daily urinary sodium and potassium excretion; did not prevent hypertension but prevented proteinuria (12 +/- 1 versus 49 +/- 3 mg/d; P < 0.01); and abrogated thrombotic microangiopathy and decreased plasma aldosterone (<16 versus 710 +/- 91 pg/ml; P < 0.001) compared with SHAM. Systolic BP in adrenalectomy + Ang II and adrenalectomy + ALDO (238 +/- 8 and 241 +/- 9 mmHg, respectively) was similar to SHAM. Despite Ang II infusion, proteinuria (17 +/- 9 mg/d) and thrombotic microangiopathy and plasma aldosterone (18 +/- 18 pg/ml) remained low but daily urinary excretion of sodium and potassium were not different from adrenalectomy + ALDO. Adrenalectomy + ALDO showed plasma aldosterone levels of 735 +/- 147 pg/ml; plasma potassium was lower; plasma creatinine and proteinuria (78 +/- 7 mg/d) were greater and thrombotic microangiopathy lesions were comparable to SHAM. These results demonstrate a pivotal role for aldosterone in the development of thrombotic microangiopathy, independent of hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874452     DOI: 10.1097/01.asn.0000078960.15147.05

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

Review 1.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

2.  Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.

Authors:  Wakako Kawarazaki; Miki Nagase; Shigetaka Yoshida; Maki Takeuchi; Kenichi Ishizawa; Nobuhiro Ayuzawa; Kohei Ueda; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

Review 3.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

Review 4.  Effect of aldosterone and MR blockade on the brain and the kidney.

Authors:  Charles T Stier; Ricardo Rocha; Praveen N Chander
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

5.  Mineralocorticoid receptor antagonism improves transient receptor potential vanilloid 4-dependent dilation of cerebral parenchymal arterioles and cognition in a genetic model of hypertension.

Authors:  Laura C Chambers; Janice M Diaz-Otero; Courtney L Fisher; William F Jackson; Anne M Dorrance
Journal:  J Hypertens       Date:  2022-09-01       Impact factor: 4.776

6.  Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats.

Authors:  Tae-Yon Chun; Praveen N Chander; Jong-Won Kim; J Howard Pratt; Charles T Stier
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

Review 7.  Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology.

Authors:  Alessandro Cannavo; Leonardo Bencivenga; Daniela Liccardo; Andrea Elia; Federica Marzano; Giuseppina Gambino; Maria Loreta D'Amico; Claudia Perna; Nicola Ferrara; Giuseppe Rengo; Nazareno Paolocci
Journal:  Oxid Med Cell Longev       Date:  2018-09-19       Impact factor: 6.543

8.  Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome.

Authors:  Khalil El Karoui; Idris Boudhabhay; Florent Petitprez; Paula Vieira-Martins; Fadi Fakhouri; Julien Zuber; Florence Aulagnon; Marie Matignon; Eric Rondeau; Laurent Mesnard; Jean-Michel Halimi; Véronique Frémeaux-Bacchi
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

Review 9.  To Curb the Progression of Fatal COVID-19 Course-Dream or Reality.

Authors:  Szymon Price; Radosław Targoński; Janusz Sadowski; Ryszard Targoński
Journal:  Curr Hypertens Rep       Date:  2021-02-27       Impact factor: 5.369

10.  Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage.

Authors:  Jing Li; Charles T Stier; Praveen N Chander; Vijay L Manthati; John R Falck; Mairéad A Carroll
Journal:  Front Pharmacol       Date:  2014-08-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.